WntResearch: Possible paradigm shift in pre-surgical treatment

Initiating Coverage



Redeye initiates coverage of WntResearch, a Swedish biotechnology company specialised in oncology. Its phase II drug candidate, Foxy-5, focuses on colon cancer and intends to decrease tumors and reduce cancer spread. Our fair value range suggests a significant upside potential in the share, and we argue that upcoming interim data and a potential licensing deal are two major catalysts in the short term.



Gustaf Meyer

Richard Ramanius

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.